

Reference number(s)
2609-A

SPECIALTY GUIDELINE MANAGEMENT

EPIDIOLEX (cannabidiol)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

Epidiolex is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Seizures associated with Lennox-Gastaut syndrome or Dravet syndrome

Authorization of 12 months may be granted for treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

1. Epidiolex [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc.; June 2018.